Lv3
230 积分 2023-11-03 加入
The new direction of drug development: Degradation of undruggable targets through targeting chimera technology
3天前
已完结
Computer-Aided Drug Discovery for Undruggable Targets
3天前
已完结
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
12天前
已完结
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
12天前
已完结
The next generation of immunotherapies for lung cancers
17天前
已完结
Global Incidence and Mortality of Gastric Cancer, 1980-2018
1个月前
已完结
Enhancing the bystander effect of antibody-drug conjugate by using a novel caspase-3 cleavable peptide linker to overcome tumor heterogeneity
1个月前
已完结
Sulfatase-cleavable linkers for antibody-drug conjugates
1个月前
已完结
Cleavable linkers in antibody–drug conjugates
1个月前
已完结
A dual-enzyme cleavable linker for antibody-drug conjugates
1个月前
已完结
皖公网安备34019202002308
